“… Although the most recent device in clinical trials, HeartMate 3 (HM3, Abbott Laboratories, Lake Bluff, IL, USA), has successfully tackled pump thrombosis, other complications such as infection, ischemic stroke, and gastrointestinal bleeding remain. Infection rates have been deemed lowered in second‐generation pumps with approximately 7% of HeartMate II (HMII; Abbott Laboratories, Lake Bluff, IL, USA) and HVAD (HeartWare Inc, Framingham, MA, USA) patients being affected. However, recent data from HeartMate 3 patients has shown an increased rate of 22%–36%.…”